Lehman Initates Amgen with 'Overweight'

Analyst Craig started coverage of the biotech sector with a positive view, based on strong growth rates and valuation

Lehman Brothers initiates the biotech sector with a positive sector view, and started coverage of Amgen (AMGN ), Genentech (DNA ), MedImmune (MEDI ) and Transkaryotic Therapies (TKTX ) with an overweight rating.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.